Literature DB >> 12915630

Pseudo-Cushing syndrome caused by fenofibrate interference with urinary cortisol assayed by high-performance liquid chromatography.

A Wayne Meikle1, James Findling, Mark M Kushnir, Alan L Rockwood, Gordon J Nelson, Alan H Terry.   

Abstract

Urinary free cortisol (UFC) excretion over 24 h reflects the production rate of cortisol and is used commonly in the diagnosis of Cushing syndrome. We report on two patients evaluated for Cushing syndrome who had elevated UFC when analyzed by HPLC but normal values for the analysis performed by RIA and HPLC-mass spectrometry/mass spectrometry (HPLC-MS/MS). Other laboratory testing was inconsistent with the diagnosis of Cushing syndrome and raised doubts about the diagnosis. We identified a probable cause of analytical interference as coming from fenofibrate (Tricor), medication taken by the patients. Fenofibrate peak overlapped with the HPLC peak of cortisol and produced an MS/MS transition overlapping the major transition of cortisol. A second MS/MS transition was free from interference. In summary, fenofibrate administration may cause false elevation of UFC values determined by HPLC or HPLC-MS/MS in patients evaluated for Cushing syndrome. An HPLC-MS/MS method using multiple mass transitions, rather than a single transition, allows accurate quantitation of urinary cortisol in patients taking fenofibrate.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12915630     DOI: 10.1210/jc.2003-030234

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Determination of cortisol production rates with contemporary liquid chromatography-mass spectrometry to measure cortisol-d(3) dilution after infusion of deuterated tracer.

Authors:  Bethany J Klopfenstein; Jonathan Q Purnell; David D Brandon; Lorne M Isabelle; Andrea E DeBarber
Journal:  Clin Biochem       Date:  2010-12-23       Impact factor: 3.281

2.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; John Newell-Price; Martin O Savage; Paul M Stewart; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2008-03-11       Impact factor: 5.958

Review 3.  Drugs and HPA axis.

Authors:  Alberto Giacinto Ambrogio; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

4.  LC-MS/MS in the Clinical Laboratory - Where to From Here?

Authors:  Stefan Kg Grebe; Ravinder J Singh
Journal:  Clin Biochem Rev       Date:  2011-02

Review 5.  Physiological basis for the etiology, diagnosis, and treatment of adrenal disorders: Cushing's syndrome, adrenal insufficiency, and congenital adrenal hyperplasia.

Authors:  Hershel Raff; Susmeeta T Sharma; Lynnette K Nieman
Journal:  Compr Physiol       Date:  2014-04       Impact factor: 9.090

6.  Quantification of cortisol in human eccrine sweat by liquid chromatography - tandem mass spectrometry.

Authors:  Min Jia; Wade M Chew; Yelena Feinstein; Perry Skeath; Esther M Sternberg
Journal:  Analyst       Date:  2016-03-21       Impact factor: 4.616

Review 7.  The diagnosis of Cushing's syndrome.

Authors:  Ty B Carroll; James W Findling
Journal:  Rev Endocr Metab Disord       Date:  2010-06       Impact factor: 6.514

8.  High variability in baseline urinary free cortisol values in patients with Cushing's disease.

Authors:  S Petersenn; J Newell-Price; J W Findling; F Gu; M Maldonado; K Sen; L R Salgado; A Colao; B M K Biller
Journal:  Clin Endocrinol (Oxf)       Date:  2013-07-15       Impact factor: 3.478

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.